FY2029 Earnings Estimate for argenex Issued By HC Wainwright

Key Points

• HC Wainwright raised argenex’s FY2029 EPS estimate to $56.38 from $53.47 and forecast FY2030 EPS of $76.63. The firm maintained a Buy rating and a $1,202 price target.
• Analyst sentiment remains positive, with argenex receiving a “Moderate Buy” consensus rating and an average price target of $1,118.28 after several firms raised their targets.
• argenex recently beat quarterly expectations, reporting $7.32 EPS versus $5.86 expected and $1.54 billion in revenue versus $1.45 billion forecast; shares were trading near their 52-week high, though valuation was elevated at roughly 40 times earnings.

argenex SE (NASDAQ:ARGX - Free Report) - Investment analysts at HC Wainwright upped their FY2029 earnings per share estimates for argenex in a note issued to investors on Tuesday, August 18th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings per share of $56.38 for the year, up from their prior forecast of $53.47. HC Wainwright currently has a "Buy" rating and a $1,202.00 target price on the stock. The consensus estimate for argenex's current full-year earnings is $29.04 per share. HC Wainwright also issued estimates for argenex's FY2030 earnings at $76.63 EPS.

Other equities research analysts have also recently issued reports about the stock. Wedbush boosted their price objective on shares of argenex from $1,050.00 to $1,150.00 and gave the company an "outperform" rating in a research report on Tuesday. Truist Financial upped their price objective on argenex from $1,030.00 to $1,095.00 and gave the stock a "buy" rating in a research report on Tuesday. Morgan Stanley increased their price objective on argenex from $1,200.00 to $1,230.00 and gave the stock an "overweight" rating in a report on Tuesday. Citigroup lifted their target price on argenex from $1,152.00 to $1,182.00 and gave the company a "buy" rating in a research report on Tuesday, July 21st. Finally, Bank of America boosted their target price on argenex from $1,016.00 to $1,088.00 and gave the company a "buy" rating in a research note on Thursday, July 2nd. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $1,118.28.

argenex Stock Performance

Shares of ARGX opened at $1,032.86 on Thursday. The firm has a market cap of $64.62 billion, a P/E ratio of 39.66, a PEG ratio of 1.03 and a beta of 0.46. argenex has a twelve month low of $651.89 and a twelve month high of $1,035.09. The firm's 50 day moving average price is $889.43 and its two-hundred day moving average price is $824.32.

argenex (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.86 by $1.46. The business had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.45 billion. argenex had a return on equity of 43.59% and a net margin of 32.19%.

Hedge Funds Weigh In On argenex

Institutional investors have recently bought and sold shares of the business. Whipplewood Advisors LLC bought a new position in shares of argenex in the first quarter valued at about $28,000. Eastern Bank bought a new stake in shares of argenex in the second quarter valued at about $32,000. Sunbelt Securities Inc. acquired a new position in shares of argenex in the third quarter valued at about $36,000. Axiom Investment Management LLC bought a new position in argenex during the first quarter worth about $50,000. Finally, WPG Advisers LLC raised its stake in argenex by 17.8% in the 1st quarter. WPG Advisers LLC now owns 86 shares of the company's stock worth $63,000 after purchasing an additional 13 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company's stock.

argenex News Summary

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Positive Phase 3 myositis data: Vyvgart Hytrulo delivered favorable ALKIVIA trial results in autoimmune myositis, supporting a potential label expansion and reducing development risk for a significant new indication. The news helped drive a sharp advance in the shares. ARGX Announces Positive Phase III Data on Vyvgart Hytrulo
• Positive Sentiment: Analysts raised price targets: Morgan Stanley increased its target to $1,230 and kept an Overweight rating; HC Wainwright raised its target to $1,202 with a Buy rating; Wedbush lifted its target to $1,150; and Citizens JMP raised its target to $1,200. Citi also initiated or reiterated a Buy rating. These targets imply additional upside and indicate growing confidence in argenx’s commercial and pipeline outlook. HC Wainwright Boosts argenx Price Target Wedbush Raises argenx Price Target Morgan Stanley Raises argenx Price Target
• Positive Sentiment: Long-term earnings expectations improved: HC Wainwright raised its FY2029 EPS forecast to $56.38 from $53.47 and its FY2030 forecast to $76.63 from $64.39. The revisions suggest analysts expect stronger Vyvgart sales and greater earnings leverage over time.
• Neutral Sentiment: argenx SE’s shares have reached a new one-year high, reflecting strong momentum, but the stock’s elevated valuation—approximately 40 times earnings—leaves it sensitive to execution, regulatory, and commercialization risks. argenx Hits New 1-Year High

About argenex

argenx NASDAQ: ARGX is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx's research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company's lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source